Building blocks of our future
Our global investment projects are the building blocks for improved healthcare and sustainability
Search
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Microbial Expertise
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins. Due to the variety of molecular formats that can be synthesised by microbes, microbial manufacturing is characterized by a broad width of production processes.
Investing in our people University of Medicine Excellence
Almost one thousand of our employees have graduated from a program developed together with Harvard Medical School’s Executive Education.
Inhaler Discussion Guide
The METAmorphosis
At Boehringer Ingelheim’s META offices in the Middle East, Turkey and Africa all offices in the region are already free of single-use plastic.
Boehringer Ingelheim China for a green future
Boehringer Ingelheim China for a green future: China employees were collecting trash on Nanhui Zui Beach for a greener future
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
Digital Transformation Within Our Global IT
Technology is at the heart of our strategy.
Grow Your Skills
Great things in business are never done by one person; they’re done by a team of people
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
ACR19 Autoimmune Trial
ACR Congress 2019 abstract analysing a subgroup of patients with autoimmune diseases in the INBUILD® trial of nintedanib in patients with PF-ILF
Generalised-Pustular-Psoriasis-Infographic
What is GPP? GPP is a rare and chronic autoinflammatory skin disease with recurrent episodes of exacerbations or flares
Powered By Our People – A Global IT Community
With state-of-the-art digital tranformation and almost 2,000 colleagues working in IT at our locations across the world, we have powered the unprecedented growth of our global IT team – the people behind our pioneering information technology progress
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Boehringer Ingelheim Access to Healthcare Strategy last mile
We aspire to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world.
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
Empowering smallholder farmers
The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
The chronic nature of generalized pustular psoriasis
Understanding the impact of the physical and psychological symptoms of this chronic disease.
Netherton Syndrome
Information on Netherton Syndrome, a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
Jan-Erik Schäfer
Jan-Erik Schäfer looks at a career with purpose
Bok Oh
Touching millions of lives with Bok Oh
History video
Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim
Systemic sclerosis physician video
In this video Professor Chris Denton (Consultant Rheumatologist) discusses his experience diagnosing systemic sclerosis, also known as scleroderma